Sartorius closes fiscal 2021 with 50 percent growth and a jump in profitability

Number of employees rises by 30 percent to nearly 14,000

27-Jan-2022 - Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability. According to preliminary figures, the company ...

WACKER Strengthens Biologics Business by Acquiring US-Based Plasmid DNA Manufacturer Genopis

Expansion of WACKER's portfolio as a contract manufacturer for the pharmaceutical industry

04-Feb-2021 - The Munich-based chemical company WACKER is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea). WACKER signed a corresponding agreement. WACKER will continue Genopis' ...

IMS Forecasts Global Pharmaceutical Market Growth of 5-8% Annually through 2014

Peak years of patent expiries shift growth toward generics

23-Apr-2010 - IMS Health reported that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion (ex manufacturer prices) over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading ...

Biomanufacturing Symposium at BIOTECHNICA 2009

Collaboration of drug developers and manufacturers

22-Sep-2009 - The second edition of this year’s Biomanufacturing Symposium on 7th October 2009 at BIOTECHNICA in Hannover (Germany), offers an ideal exchange platform for biopharma drug developers and manufacturers. This one-day event jointly organised by Capgemini Consulting and Deutsche Messe will address ...

CMC Acquires Former ICOS Biologics Operation in Bothell, Washington State, USA

CMC Biopharmaceuticals to purchase facility from Lilly; will retain existing employees

05-Dec-2007 - CMC Biopharmaceuticals A/S (CMC) announced that it has reached an agreement to buy the biologics development and manufacturing operation that Eli Lilly and Company acquired when it purchased ICOS Corporation in January 2007. CMC, a Copenhagen based leading provider of contract biomanufacturing ...

UK consortium led by Paraytec Ltd to develop analytical instrumentation to detect aggregation in biopharmaceutical processing

04-Dec-2007 - A multi-disciplinary UK consortium of partners including Avecia, Intertek ASG, Lonza, Paraytec and the University of Bradford has recently been awarded research grants by the Technology Strategy Board and the Engineering and Physical Sciences Research Council. The part funded £1M+ project is to ...

Beiersdorf affiliate Nivea Seoul Ltd. enters alliance for product distribution in Korean wound healing market

07-Jul-2006 - NIVEA Seoul Ltd., the Korean affiliate of Beiersdorf, entered a strategic alliance with Green Cross Corporate (GCC). The contract signing ceremony for Hansaplast distribution took place in June. The alliance aims to build a business platform for the launch of plasters in 2007. In Korea, the ...

Rap.ID's Particle Explorer Identifies Particles In Products of the Growing Pharmaceuticals Market

27-Jun-2005 - Since December, the development and quality assurance of new types of biopharmaceuticals at a major pharma company in Eastern Switzerland have been facilitated through the use of rap.ID Particle Systems' Liquid Particle Explorer. The particle analysis system allows the customer, who is ...

API Companies Look for Solutions to Problems of Overcapacity

Lack of Capability Differentiation and Competition from Low-cost Manufacturers

30-Nov-2004 - Manufacturers in the crowded and highly fragmented European active pharmaceutical ingredients (API) market are struggling to overcome a variety of challenges. One of the most pressing of these is the problem of overcapacity. Additionally, constant price erosions and the large number of ...

Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement

29-Nov-2001 - Boehringer Ingelheim International GmbH and ImmunoGen, Inc. (Nasdaq: IMGN) today announced a collaboration to develop a new product combining ImmunoGen’s maytansinoid Tumor-Activated Prodrug (TAP) technology with a Boehringer Ingelheim antibody. Under the terms of the agreement, Boehringer ...